948 related articles for article (PubMed ID: 28073178)
1. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
2. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207
[TBL] [Abstract][Full Text] [Related]
3. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
4. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.
Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD010253. PubMed ID: 24901467
[TBL] [Abstract][Full Text] [Related]
5. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
6. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Karpe KM; Talaulikar GS; Walters GD
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 2 receptor antagonists for kidney transplant recipients.
Webster AC; Ruster LP; McGee R; Matheson SL; Higgins GY; Willis NS; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD003897. PubMed ID: 20091551
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
9. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
[TBL] [Abstract][Full Text] [Related]
11. Antibody induction versus corticosteroid induction for liver transplant recipients.
Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010252. PubMed ID: 24880007
[TBL] [Abstract][Full Text] [Related]
12. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster A; Pankhurst T; Rinaldi F; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2006 Apr; (2):CD004756. PubMed ID: 16625610
[TBL] [Abstract][Full Text] [Related]
13. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients.
Montero N; Webster AC; Royuela A; Zamora J; Crespo Barrio M; Pascual J
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD007669. PubMed ID: 25220222
[TBL] [Abstract][Full Text] [Related]
14. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive agents for treating IgA nephropathy.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
[TBL] [Abstract][Full Text] [Related]
16. Steroid avoidance or withdrawal for kidney transplant recipients.
Haller MC; Royuela A; Nagler EV; Pascual J; Webster AC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD005632. PubMed ID: 27546100
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials.
Zheng J; Song W
Medicine (Baltimore); 2017 Jul; 96(28):e7151. PubMed ID: 28700465
[TBL] [Abstract][Full Text] [Related]
18. Steroid avoidance or withdrawal for kidney transplant recipients.
Pascual J; Zamora J; Galeano C; Royuela A; Quereda C
Cochrane Database Syst Rev; 2009 Jan; (1):CD005632. PubMed ID: 19160257
[TBL] [Abstract][Full Text] [Related]
19. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
20. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]